<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00840099</url>
  </required_header>
  <id_info>
    <org_study_id>02-543</org_study_id>
    <nct_id>NCT00840099</nct_id>
  </id_info>
  <brief_title>600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions</brief_title>
  <official_title>An Open-Label, Single-Dose, Two-Way Crossover Bioequivalence Study of Two Oral Suspension Formulations of Amoxicillin/Clavulanate Potassium, 600/42.9 mg/5 mL in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the bioequivalence between Amoxicillin and
      Clavulanate Potassium for Oral Suspension, 600/42.9 mg/5 mL and Augmentin ES-600™ for Oral
      Suspension, 600/42.9 mg/5 mL in healthy, male and female subjects, under fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria

      Statistical Methods: FDA bioequivalence statistical methods
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">August 2002</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence Based on Cmax for Amoxicillin</measure>
    <time_frame>Blood samples collected over 14 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence Based on AUC0-Inf for Amoxicillin</measure>
    <time_frame>Blood samples collected over 14 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence Based on AUC0-t for Amoxicillin</measure>
    <time_frame>Blood samples collected over 14 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence Based on Cmax for Clavulanic Acid</measure>
    <time_frame>Blood samples collected over 14 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence Based on AUC0-Inf for Clavulanic Acid</measure>
    <time_frame>Blood samples collected over 14 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence Based on AUC0-t for Clavulanic Acid</measure>
    <time_frame>Blood samples collected over 14 hour period</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL</intervention_name>
    <description>1 x 600 mg/42.9 mg/5 mL, single-dose fed</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Augmentin ES-600™ 600 mg/42.9 mg/5 mL Suspension</intervention_name>
    <description>1 x 600 mg/42.9 mg/5 mL, single-dose fed</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, non-smoking male or non-pregnant, non-lactating female subjects, 18 years of
             age and over.

          -  Body weight within ±15% of the appropriate weight range published in 1993 by
             Metropolitan Life Insurance Company, Statistical Bureau and body-mass index (BMI) less
             than 30.

          -  Negative for:

               -  HIV

               -  Hepatitis B and C

               -  Urine drugs of abuse test (marijuana, amphetamines, barbiturates, cocaine,
                  opiates, benzodiazepines and methadone).

               -  Cotinine (urine test)

               -  Breath alcohol (Breathalyzer)

               -  HCG (females only)

          -  No significant diseases or clinically significant abnormal laboratory values.

          -  No clinically significant findings in the physical examination.

          -  No clinically significant findings in vital sign measurements and 12-lead
             electrocardiogram (ECG).

          -  Informed of the nature of the study and give written consent prior to receiving any
             study medication.

          -  Female subjects: surgically steril, post-menopausal or practicing a recognized safe
             method of contraception (abstention, oral or implanted contraceptives, intra-uterine
             device or consistent condom plus spermicide use).

        Exclusion Criteria:

          -  Known history or presence of any disease or condition which might compromise the
             following body systems: immunologic, endocrine, renal, cardiovascular, respiratory,
             hematologic, gastrointestinal, neurologic, hepatic, psychiatric or dermatologic

          -  More specifically: history or presence of significant: sensitivity to multiple
             allergens, diarrhea, stomach or intestinal disease, mononucleosis, renal or hepatic
             dysfunction and asthma.

          -  Known or suspected carcinoma.

          -  Known history or presence of:

               -  Hypersensitivity or idiosyncratic reaction to amoxicillin, clavulanic acid,
                  penicillins, cephalosporins and/or any other β-lactamase inhibitors.

               -  Clavulin-associated jaundice/hepatic dysfunction.

               -  Alcoholism within last 12 months.

               -  Drug dependence and/or substance abuse.

               -  Use of tobacco or nicotine-containing products, within last 12 months.

          -  On a special diet within 4 weeks prior to drug administration (i.e. a deliberate
             change in diet for any reason).

          -  Participation in another clinical trial or received an investigational product in the
             previous 30 days prior to drug administration.

          -  Donation up to 250 mK of blood in the previous 30 days, 251-500 mKL in the previous 45
             days, 501-750 mL in the previous 60 days or above 750 mL in the previous 90 days prior
             to study start.

          -  Requirement of any medication, (prescription and/or over-the-counter) or dietary
             supplements on a routine basis, with the exception of occasional use of acetaminophen
             and oral or implanted contraceptives.

          -  Difficulty fasting or consuming the standard prescribed meals.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xueyu (Eric) Chen, M.D., Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharma Medica Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharma Medica Research Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M1R 5A3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2009</study_first_posted>
  <results_first_submitted>May 18, 2009</results_first_submitted>
  <results_first_submitted_qc>July 8, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 25, 2009</results_first_posted>
  <last_update_submitted>July 8, 2009</last_update_submitted>
  <last_update_submitted_qc>July 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test First</title>
          <description>Amoxicillin and Clavulante Potassium for Oral Suspension, 600/42.9 mg/5mL test product dosed in first period followed by AugmentinES-600™ for Oral Suspension 600/42.9 mg/5mL reference product dosed in second period</description>
        </group>
        <group group_id="P2">
          <title>Reference First</title>
          <description>AugmentinES-600™ for Oral Suspension 600/42.9 mg/5mL reference product dosed in first period followed by Amoxicillin and Clavulante Potassium for Oral Suspension 600/42.9 mg/5mL test product dosed in second period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21">3 subjects were dismissed from study prior to period 2 dosing</participants>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test First</title>
          <description>Amoxicillin and Clavulante Potassium for Oral Suspension, 600/42.9 mg/5mL test product dosed in first period followed by AugmentinES-600™ for Oral Suspension 600/42.9 mg/5mL reference product dosed in second period</description>
        </group>
        <group group_id="B2">
          <title>Reference First</title>
          <description>AugmentinES-600™ for Oral Suspension 600/42.9 mg/5mL reference product dosed in first period followed by Amoxicillin and Clavulante Potassium for Oral Suspension 600/42.9 mg/5mL test product dosed in second period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on Cmax for Amoxicillin</title>
        <description>Cmax - Maximum Observed Concentration</description>
        <time_frame>Blood samples collected over 14 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin Clavulanate</title>
            <description>Amoxicillin and Clavulante Potassium for Oral Suspension, 600/42.9 mg/5mL test product dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>AugmentinES-600™</title>
            <description>AugmentinES-600™ for Oral Suspension 600/42.9 mg/5mL reference product dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on Cmax for Amoxicillin</title>
          <description>Cmax - Maximum Observed Concentration</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10970.75" spread="3084.93"/>
                    <measurement group_id="O2" value="10867.32" spread="3136.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA</non_inferiority_desc>
            <param_type>Test/Reference Ratio of Means x 100</param_type>
            <param_value>100.91</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>95.82</ci_lower_limit>
            <ci_upper_limit>106.26</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on AUC0-inf for Amoxicillin</title>
        <description>AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
        <time_frame>Blood samples collected over 14 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin Clavulanate</title>
            <description>Amoxicillin and Clavulante Potassium for Oral Suspension, 600/42.9 mg/5mL test product dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>AugmentinES-600™</title>
            <description>AugmentinES-600™ for Oral Suspension 600/42.9 mg/5mL reference product dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on AUC0-inf for Amoxicillin</title>
          <description>AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27965.57" spread="5011.89"/>
                    <measurement group_id="O2" value="27147.08" spread="4862.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>102.79</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>100.69</ci_lower_limit>
            <ci_upper_limit>104.94</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on AUC0-t for Amoxicillin</title>
        <description>AUC0-t - Area under the concentration-time curve from time zero to the time of last non-zero concentration</description>
        <time_frame>Blood samples collected over 14 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin Clavulanate</title>
            <description>Amoxicillin and Clavulante Potassium for Oral Suspension, 600/42.9 mg/5mL test product dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>AugmentinES-600™</title>
            <description>AugmentinES-600™ for Oral Suspension 600/42.9 mg/5mL reference product dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on AUC0-t for Amoxicillin</title>
          <description>AUC0-t - Area under the concentration-time curve from time zero to the time of last non-zero concentration</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27464.27" spread="4977.06"/>
                    <measurement group_id="O2" value="26666.90" spread="4809.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>102.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>100.62</ci_lower_limit>
            <ci_upper_limit>104.93</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on Cmax for Clavulanic Acid</title>
        <description>Cmax - Maximum Observed Concentration</description>
        <time_frame>Blood samples collected over 14 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin Clavulanate</title>
            <description>Amoxicillin and Clavulante Potassium for Oral Suspension, 600/42.9 mg/5mL test product dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>AugmentinES-600™</title>
            <description>AugmentinES-600™ for Oral Suspension 600/42.9 mg/5mL reference product dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on Cmax for Clavulanic Acid</title>
          <description>Cmax - Maximum Observed Concentration</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1127.59" spread="338.93"/>
                    <measurement group_id="O2" value="1106.84" spread="353.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the Mean x 100</param_type>
            <param_value>100.47</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>93.28</ci_lower_limit>
            <ci_upper_limit>108.20</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on AUC0-inf for Clavulanic Acid</title>
        <description>AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
        <time_frame>Blood samples collected over 14 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin Clavulanate</title>
            <description>Amoxicillin and Clavulante Potassium for Oral Suspension, 600/42.9 mg/5mL test product dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>AugmentinES-600™</title>
            <description>AugmentinES-600™ for Oral Suspension 600/42.9 mg/5mL reference product dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on AUC0-inf for Clavulanic Acid</title>
          <description>AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2396.58" spread="753.32"/>
                    <measurement group_id="O2" value="2260.40" spread="731.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA</non_inferiority_desc>
            <param_type>Ratio of the mean</param_type>
            <param_value>104.15</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>96.35</ci_lower_limit>
            <ci_upper_limit>112.58</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 80% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on AUC0-t for Clavulanic Acid</title>
        <description>AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration</description>
        <time_frame>Blood samples collected over 14 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin Clavulanate</title>
            <description>Amoxicillin and Clavulante Potassium for Oral Suspension, 600/42.9 mg/5mL test product dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>AugmentinES-600™</title>
            <description>AugmentinES-600™ for Oral Suspension 600/42.9 mg/5mL reference product dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on AUC0-t for Clavulanic Acid</title>
          <description>AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2293.69" spread="747.25"/>
                    <measurement group_id="O2" value="2157.07" spread="719.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>104.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>95.85</ci_lower_limit>
            <ci_upper_limit>112.97</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>Teva Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

